The appointment of US Biotech Veteran Dr. Rosenblatt and U.S. Biopharma Exec Jason Haddock to the Board of Directors have certainly provided the much oxygen needed in an otherwise lifeless consolidation for months. PYC is beginning to have a formidable team of high calibre veterans, deeply experienced in areas critical to the clinical phase and commercialisation of lead drug VP-001.
As mentioned in my last post, dealing with large animals especially the monkey in clinical testing is not a child's play. Even keeping them well fed, healthy and emotionally steady is quite a task. A rabbit is easy to hold down for an injection and extraction of blood/tissue for haematological and histopathological profile. But a monkey would be very challenging and drugging it beforehand would contaminate the results.
In a similar preclinical toxicity test of a DNA drug, as per the regulatory requirements, the study was designed for acute (single dose - 14 days), sub-chronic (repeat dose - 28 days) and chronic (intended clinical dose - 120 days) toxicity tests using three dose levels, viz. therapeutic, average (2x therapeutic dose) and highest dose (10 x therapeutic dose) exposure in monkeys. This is something you could not hurry. @travelbug2 has already pointed out in his Post #: 52304923 that the tox readout might be moved into H2/2012. They might have underestimated the efforts required for monkey business (read the article from NCBI per URL below). It would not have any negative connotations that the tox result is bad. Just look as the solid tox results in the mouse model thus far: "PYC has seen good target engagement in the eye across 1.6, 3.2, and 6.4 micrograms with no major increase in toxicity markers, and then when injected systemically there were no elevation in toxicity markers at 30mg/kg!"
Daily Chart TA Analysis (refer to Chart #1)
- SP broke above the sideway consolidation box for 2nd week.
- SP tracking along top of Bollinger band and middle of blue channel.
- SP now way above 20MA and 200MA which is a sign of strength.
My 4 favourite TA indicators
- Fast Stochastic crossed up and above 50 = Strong BUY
- MACD flipped up well above 0 = Strong BUY
- RSI continues to trend above 50 for over a month = Strong BUY
- Slow Stochastic flipped up and down in Overbought Zone = BUY / HOLD
- Overall it is a Strong BUY
Useful links:
- https://bit.ly/3ujFIUO?trk=organization-update_share-update_update-text
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734712/
These are my analysis and TA thoughts, DYOR! If you would like more of these charts and analysis, please click the "Great analysis" button for encouragement.
- Forums
- ASX - By Stock
- PYC
- PYC Chart looks the goods
PYC Chart looks the goods, page-260
Featured News
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.0¢ |
Change
0.010(5.26%) |
Mkt cap ! $933.2M |
Open | High | Low | Value | Volume |
19.0¢ | 20.0¢ | 18.8¢ | $963.9K | 4.978M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2692 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 445208 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2692 | 0.190 |
5 | 135217 | 0.185 |
10 | 456952 | 0.180 |
5 | 223750 | 0.175 |
12 | 452263 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 445208 | 3 |
0.205 | 650000 | 5 |
0.210 | 1048799 | 10 |
0.215 | 870300 | 4 |
0.220 | 944571 | 2 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online